Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study
-
Published:2023-12-21
Issue:1
Volume:41
Page:
-
ISSN:1559-131X
-
Container-title:Medical Oncology
-
language:en
-
Short-container-title:Med Oncol
Author:
Noronha Vanita, Patil Vijay, Menon Nandini, Kalra Devanshi, Singh Ajaykumar, Shah Minit, Goud Supriya, Jobanputra Kunal, Nawale Kavita, Shah Srushti, Chowdhury Oindrila Roy, Mathrudev Vijayalakshmi, Jogdhankar Shweta, Singh Madhu Yadav, Singh Ashish, Adak Supriya, Sandesh Mayuri, Arunkumar R., Kumar Suman, Mahajan Abhishek, Prabhash KumarORCID
Funder
Lung Cancer Consortium Asia
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference36 articles.
1. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Jr Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan WZ, Hong RL, GonzálezMendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7. 2. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27. https://doi.org/10.1056/NEJMoa0802656. (PMID: 18784101). 3. Patil V, Abraham G, Ravikrishna M, Bhattacharjee A, Noronha V, Parekh D, Menon N, Bajpai J, Prabhash K. Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India. Ecancermedicalscience. 2022;3(16):1464. 4. Rajappa SJ, Pinninti R. Real-world evidence with nivolumab in head-and-neck cancer: access is key! Cancer Res Stat Treat. 2022;5(3):541–3. 5. Patil V, Muthuluri H, Choudhary J, Parekh D, Abraham G, Noronha V, et al. Nivolumab in platinum-refractory head-and-neck cancers—retrospective observational audit from a tertiary cancer center. Cancer Res Stat Treat. 2022;5:468–73.
|
|